A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Prior treatment

• According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;
• Within 90 days before baseline, the study eye had received anti-VEGF treatment;
• Within 90 days before baseline, the study eye had received anti-complement treatment;
• At any time before baseline, the study eye had received IBI302 treatment;

Other illness

• There is an active intraocular or periocular infection or inflammation in either eye;
• The non-study eye has severe visual function disorders;
• Uncontrollable hypertension;

Lab values

• Glycated hemoglobin (HbA1c) \> 10.0% within 28 days prior to screening;

Other

• The study eye has uncontrollable glaucoma;
• Other exclusion criteria set by protocol.

• Have signed an informed consent form before participating in the research.
• Male or female individuals aged 50 or above at the time of signing the informed consent form;
• Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
• At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).